Cell子刊：谢青/谢岑合作揭示识别脂肪肝患者显著纤维化和炎症的血液代谢组学检测指标

Core Insights - The article discusses the increasing global health issue of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), previously known as Non-Alcoholic Fatty Liver Disease (NAFLD), highlighting its progression to Metabolic Dysfunction-Associated Steatohepatitis (MASH) and the associated risks of morbidity and mortality [1][4]. Group 1: Research Findings - A recent study published in Cell Reports Medicine identified blood metabolic panels that can detect significant fibrosis and inflammation in MASLD patients, revealing key metabolites such as Guanidinoacetic Acid (GAA) and Decanoic Acid (SA) that show therapeutic potential in mouse models [2][5]. - The research involved 293 participants across three independent cohorts, utilizing machine learning techniques to develop a non-invasive diagnostic model for detecting significant fibrosis (≥F2) and moderate to severe inflammation (≥I2) [4]. - The area under the receiver operating characteristic curve (AUROC) for fibrosis detection reached 0.928, 0.829, and 0.806 in the discovery, validation cohort 1, and validation cohort 2, respectively, outperforming existing indices like FIB-4 and APRI [4]. Group 2: Implications for Diagnosis and Treatment - The study's findings provide a systematic exploration of the key metabolic features of MASLD, paving the way for new non-invasive diagnostic and treatment strategies [7]. - The identified metabolites GAA and SA can improve liver fat deposition, inflammation, and fibrosis through dual mechanisms of "regulating lipid metabolism" and "promoting inflammation resolution," indicating their potential in advancing MASLD management [5].